SEC Form 4 · accession 0001179022-15-000012
GALECTIN THERAPEUTICS INC · GALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James C Czirr
Officer — Executive Chairman · Director
Period of report
Jan 31, 2015
Accepted (ET)
Feb 3, 2015 · 5:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001133416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock | Jan 31, 2015 | M | 166,667 | $1.80 | A | 976,798 | D | |
| Common stockF1 | Jan 31, 2015 | F | 93,168 | $3.22 | D | 883,630 | D | |
| Common stockF2 | holding | — | — | — | 2,776,186 | I | by 10X Fund, L.P. |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F3,F4 | $1.80 | Jan 31, 2015 | M | 166,667 | D | — | Feb 1, 2015 | Common stock | 166,667 | 0 | D |
Explanation of responses
- F1Represents shares forfeited in satisfaction of exercise price of vested options.
- F2Reporting person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., a Delaware limited partnership, and as such may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- F3Amount reflects the Issuer's 1-for-6 reverse stock split on March 23, 2012.
- F4The options are fully vested and exercisable.